Article
Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
Neuroscience letters - 12 Jun 2003
Borroni Barbara, Pettenati Carla, Bordonali Tania, Akkawi Nabil, Di Luca Monica, Padovani Alessandro
Abstract excerpt
The clinical, genetic or biological variables which regulate long-term efficacy of cholinesterase inhibitors (ChEIs) in Alzheimer disease (AD) are still unknown and it is not possible to predict who will benefit from the treatment. In this study we showed that high cholesterol levels correlated with faster decline at 1-year follow-up in AD patients on ChEIs. These findings suggest that serum cholesterol is a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.